Search
Filter Results
Displaying 41–50 of 800 for “retinitis clinical trial”
-
May 24, 2022
Luxa Doses First Participant in Clinical Trial of RPE Stem Cells for Dry AMD Patients
The company’s RPESC-RPE cell product is composed of progenitor-stage RPE cells grown from human eyes donated to eye banks.
-
Dec 4, 2018
ProQR Receives FDA Authorization to Launch Clinical Trial for USH2A Therapy
ProQR, a biotech in the Netherlands developing therapies for rare diseases, has received authorization from the US Food and Drug Administration to launch a Phase I/II clinical trial for QR-421a, its treatment targeting mutations in exon 13 of the USH2A gene.
-
Aug 31, 2023
SparingVision Recruiting for Clinical Trial of Cone-Preserving Gene Therapy for RP
First cohort of patients has been dosed in Phase ½ clinical trial taking place in Pittsburgh and Paris
-
Feb 27, 2020
Researchers Report Six-Month Results from Biogen-Sponsored XLRP Gene Therapy Clinical Trial
Vision improvements observed with medium and high doses
-
Mar 20, 2017
First Patient Treated in XLRP Gene Therapy Clinical Trial
The Nightstar gene therapy involves injection of healthy copies of RPGR underneath the retina.
-
Jul 25, 2019
Allergan and Editas Begin Recruiting for CRISPR/Cas9 Clinical Trial for LCA10
The trial will be the first for a CRISPR/Cas9 therapy administered inside the human body.
-
Oct 29, 2019
Iveric Bio’s Therapy Slows Retinal Degeneration in Phase 2b Trial for Dry AMD
Zimura inhibits a complement protein known as C5, a component of the immune system that, when overactive, can cause retinal degeneration.
-
Nov 8, 2023
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
The company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
Sep 5, 2018
Vision Improvements Reported in ProQR's Clinical Trial for LCA10 Treatment
The company reported that 60 percent of subjects in the trial demonstrated improvements in visual acuity and their ability to navigate a mobility course. The treatment was also safe for patients.
-
Feb 15, 2022
ProQR’s Phase 2/3 Clinical Trial for LCA10 RNA Therapy Doesn’t Meet Endpoints
The emerging treatment had shown encouraging results in a Phase ½ clinical trial